PLRG1
Pleiotropic regulator 1
Protein Summary
Involved in pre-mRNA splicing as component of the spliceosome (PubMed:28502770, PubMed:28076346). Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing (PubMed:11101529, PubMed:11544257). This gene encodes a core component of the cell division cycle 5-like (CDC5L) complex. The CDC5L complex is part of the spliceosome and is required for pre-mRNA splicing. The encoded protein plays a critical role in alternative splice site selection. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2011]
- ENST00000302078
- ENSP00000303191
- ENSG00000171566
- ENST00000499023
- ENSP00000424417
- Cwc1
- PRL1
- PRP46
- PRPF46
- TANGO4
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 1 | ||
disease perturbation | 0.83 | ||
histone modification site profile | 0.82 | ||
kinase perturbation | 0.81 | ||
transcription factor binding site profile | 0.79 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 28.11 (req: < 5)
Gene RIFs: 4 (req: <= 3)
Antibodies: 241 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 28.11 (req: >= 5)
Gene RIFs: 4 (req: > 3)
Antibodies: 241 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0